BioNotebook: Aegerion lawsuit, Juno funding, Concert IPO, Salix layoffs
This article was originally published in Scrip
Executive Summary
Several biotechnology and specialty pharmaceutical companies announced deals and corporate updates during the week of the 32nd Annual JP Morgan Healthcare Conference in San Francisco, which ended on 16 January, and a lot of news was lost in the hubbub of the yearly kickoff event for the biopharma industry. Companies probably are happy to have some news ignored, such as shareholder litigation and employee layoff notices. But in a closely-watched industry with skyrocketing public company values, relevant information eventually comes to light.
You may also be interested in...
Better Together? Aegerion And QLT Merge To Solve Problems
Aegerion and QLT will unite to create a new company dubbed Novelion in a deal that could help both companies solve some long-standing issues.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.